Prognostic and predictive role of lactate dehydrogenase 5 ( LDH5) expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) anti-angiogenic therapy

PURPOSE: The CONFIRM randomized trials, investigating the role of the VEGF-receptor inhibitor PTK787/ZK 222584 (vatalanib) in colorectal cancer (FOLFOX 4 ± vatalanib), showed some benefit in patients with high serum LDH levels. Here we investigated the expression of LDH5 (encoded entirely by the LDH...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Koukourakis, Michael I., Giatromanolaki, Alexandra, Sivridis, Efthimios, Gatter, Kevin C., Trarbach, Tanja, Folprecht, Gunnar, Shi, Michael M., Lebwohl, David, Jalava, Tarja, Laurent, Dirk, Meinhardt, Gerold, Harris, Adrian L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3145151/
https://ncbi.nlm.nih.gov/pubmed/21632858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2918
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares